What should be considered when choosing an acute myeloid leukemia (AML) treatment path? Dr. Pinkal Desai explains the factors that are considered to determine the best treatment for an individual patient.
Dr. Pinkal Desai is Assistant Professor of Medicine at Weill Cornell Medical College and a hematologist specializing in acute myeloid leukemia (AML) at Weill Cornell Medicine. Learn more about Dr. Desai, here: [ Ссылка ].
Patient Empowerment Network (PEN) is a 501(c)(3) non-profit organization. PEN’s mission is to fortify cancer patients and care partners with the knowledge and tools to boost their confidence, put them in control of their healthcare journey, and assist them in receiving the best, most personalized care available to ensure they have the best possible outcome. Subscribe now to receive the latest news on cancer treatment and research: powerfulpatients.org/connect
Choosing an AML Treatment Path: What Should You Consider?
Теги
Acute Myeloid LeukemiaAMLAcute Myelogenous LeukemiaAML treatmenttherapy genetic testingDr. Pinkal Desaiacute leukemia treatmentclinical trialsclinical studiestherapyCytogeneticsfluorescence in situ hybridizationFISHMolecular Testingnext generation sequencingFLT3 InhibitorsIDH InhibitorsBCL-2 inhibitorsvenclextaMLL RearrangementFLT3IDH1IDH2NPM1MLLASXL1RUNX1FDAFDA approvalhematologyblood cancergene mutations